Efungumab is a drug developed by NeuTec Pharma (a subsidiary of Novartis

Novartis

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry...

), intended to treat invasive

Fungemia

-Pathogens:The most commonly known pathogen is Candida albicans, causing roughly 70% of fungemias, followed by Candida glabrata with 10%, Aspergillus with 1% and Saccharomyces as the fourth most common. However, the frequency of infection by C. glabrata, Saccharomyces boulardii, Candida tropicalis,...

 Candida infection

Candidiasis

Thrush redirects here. For the hoof infection see Thrush .Candidiasis or thrush is a fungal infection of any of the Candida species , of which Candida albicans is the most common...

 in combination with amphotericin B

Amphotericin B

Amphotericin B is a polyene antifungal drug, often used intravenously for systemic fungal infections...

. The European Medicines Agency

European Medicines Agency

The European Medicines Agency is a European agency for the evaluation of medicinal products. From 1995 to 2004, the European Medicines Agency was known as European Agency for the Evaluation of Medicinal Products.Roughly parallel to the U.S...

 has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues.

Chemically, efungumab is a single-chain variable fragment of a human

Human

Humans are the only living species in the Homo genus...

 monoclonal antibody.
As such, it potentially act similarly to an IgA

IGA

Iga or IGA may stand for:-Given name:* a female given name of Polish origin. The name originates from the female given name Jadwiga and stands for gia,or gina in the USA....

- inhibiting by binding and blocking.